Cemiplimab
Author: Dustin Phan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Cemiplimab (Regeneron/Sanofi) is a programmed death-1 (PD-1)-targeted monoclonal antibody. The interaction between PD-1 and its ligand PD-L1 on a T cell reduces T-cell function signals, resulting in tumor cell survival and proliferation due to immune system suppression. The disruption of this interaction reduces the ability of the tumor to evade immune system targeting and enhances antitumor immune responses.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 cemiplimab : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
9 Figure 45: Datamonitor Healthcare’s drug assessment summary for Tagrisso in non-small cell lung cancer
13 Figure 32: Datamonitor Healthcare’s drug assessment summary for Imfinzi in non-small cell lung cancer
LIST OF TABLES
6 Table 1: Cemiplimab drug profile
7 Table 2: Cemiplimab Phase III trials in non-small cell lung cancer
8 Table 3: Cemiplimab early-phase data in non-small cell lung cancer
14 Table 4: Cemiplimab sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
16 Table 5: Cemiplimab patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
10 Table 46: Gilotrif patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Portrazza 
Sign up to the